Evaluation of the Control Level of Asthmatic Patients With Seasonal Increase of Respiratory Symptoms (High and/or Low) (SAISON)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00882128
First received: April 15, 2009
Last updated: November 13, 2009
Last verified: November 2009
  Purpose

To evaluate the level of control of Asthma (GINA : controlled, partially controlled, not controlled) of asthmatic patients consulting their general practitioner for a seasonal increase of respiratory symptoms (high and / or low) whether an inhaled corticotherapy is taken or not.


Condition
Asthma
Respiratory Symptoms

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Evaluation of the Control Level (GINA) of Asthmatic Patients Consulting Their General Practitioner for a Seasonal Increase of Respiratory Symptoms (High and / or Low), Whether an Inhaled Corticotherapy is Taken or Not

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Evaluate the control level of Asthma of asthmatic patients consulting their GP for a seasonal increase of respiratory symptoms (high/low) with an inhaled corticotherapy or not. [ Time Frame: One shot (patients will only have one visit to attend - this visit will take place between May 09 and September 09) ] [ Designated as safety issue: No ]

Estimated Enrollment: 3300
Study Start Date: May 2009
Study Completion Date: October 2009

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The first 3 consecutive adult and asthmatic patients consulting their general practitioner for a seasonal increase of respiratory symptoms (high and / or low) and treated with PRN fast acting bronchodilatator alone or associated with inhaled IGCS, excluding all other treatments for asthma.

Criteria

Inclusion Criteria:

  • Asthmatic adults consulting for a seasonal increase of respiratory symptoms (high/low) and treated with PRN fast acting bronchodilator alone or associated with inhaled IGCS, excluding all other treatments for asthma.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00882128

  Show 1054 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Castaigne Castaigne AstraZeneca
  More Information

No publications provided

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00882128     History of Changes
Other Study ID Numbers: NIS-RFR-DUM-2008/2
Study First Received: April 15, 2009
Last Updated: November 13, 2009
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
Asthma seasonal respiratory symptoms
Asthmatic patients with increase of respiratory symptoms

Additional relevant MeSH terms:
Asthma
Signs and Symptoms, Respiratory
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on August 20, 2014